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ABSTRACT
Objective: Polycystic ovarian syndrome (PCOS) is a complex disease occurred throw genital period of women depends on the age, genetic factors, and 
ethnicity. Monocyte Chemoattractant Protein-1 (MCP-1) has been implicated in the metabolic disturbances and menstrual irregularities.
Methods: In the biochemical test, the blood was collected in plain tubes then separated by centrifugation. Serum was collected in test tubes then, MCP, 
haemoglobin (Hb), packed cell volume (PCV), fasting blood glucose (FBG), urea, creatinine, prolactin, testosterone, luteinizing hormone (LH), follicle 
stimulating hormone (FSH), T3, T4, and thyroid-stimulating hormone (TSH) were determined by enzyme-linked immune-sorbent assay and relevant 
clinical features were collected simultaneously in all subjects.
Results: The results showed no significant increased in means of age, body mass index in PCOS women (patients) when compared with healthy 
subjects (control groups) also there was no significant decreased in levels of Hb, PCV while increased in FBG, urea and creatinine in PCOS women 
when compared with healthy subjects. In addition, mean of LH and 17 β-Estradiol were no significant increased except the significantly increased in 
the ratio of LH/FSH, prolactin, and testosterone, while FSH was significantly decreased in PCOS women when compared with healthy subjects. Levels 
of triiodothyronine (T3) and thyroxine (T4) were found significantly decreased while an increased level of TSH when compared with healthy subjects. 
Finally, MCP-1 was showed significantly increased in PCOS women when compared with healthy subjects.
Conclusions: It can be concluded that PCOS women might suffer from changes in the levels of MCP-1(an inflammation marker). Besides, it was detected that 
TSH might be responsible related metabolic disturbances could be related to TSH and MCP which can be considered as relevant features in such disturbances.
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INTRODUCTION
Polycystic ovarian syndrome (PCOS) is endocrine disease causes 
infertility, acne, hirsutism, and irregular periods, with insulin 
resistance [1,2]. The follicles in each ovarian outside about 10–15 
with most of them generally small or immature than average caused 
infertility [3]. Many factors are thought to be responsible for its 
pathophysiology such as ethnicity, genetic, multiple endocrine, and 
metabolic abnormalities [4,5]. In addition to, environmental factors 
such as physical activity, lifestyle, and diet [6]. Insulin resistance, 
hyperandrogenemia, and PCOS are associated with pro-inflammatory 
status caused by oxidative stress [7]. The production of reactive 
oxygen species is increased by hyperglycemia associated with PCOS [8] 
Elevated androgen which leads to overproduction of gonadotropins 
particularly luteinizing hormone (LH) [9] together with high insulin 
level leads to follicular growth arrest that initiates anovulation [10]. 
Anovulation in PCOS women is often associated with estradiol (E2) 
secretion and progesterone production [11]. PCOS women present 
with phenotypes according to ESHRE guidelines [12] endocrine 
irregularities including abnormally high levels of LH, follicle stimulating 
hormone (FSH), FSH/ LH, prolactin, estradiol, testosterone, and insulin 
resistance [13,14]. Moreover, PCOS women may be presented with 
nodular goiter associated with this syndrome [15,16]. Many studies 
showed disorder in tri-iodothyronine (T3) level and anti-thyroid 
peroxidase antibody in PCOS patients [17]. Hypothyroidism has been 
associated increase of sex hormone-binding globulin levels [18] these 
actions effected on the osteoblast cells [19]. The treatment aimed in the 
regulation of menses and recover of fertility [20]. The first-line therapy 
is the lifestyle modification, oral pharmacological agents such as 
clomiphene and metformin, which lower the level of insulin resistance 
and induce ovulation [21]. Besides, it was found that Vitamin D and 
metabolic modulations [22]. Monocyte chemoattractant protein-1 
(MCP-1) and Macrophage inflammatory protein-1 closely related to 
metabolic syndrome presence of chronic low-grade inflammation in 
women with this syndrome are emerging [23]. MCP-1 is expressed and 
secreted by adipocyte, which has been reported to be involved in the 
recruitment and activation of peripheral blood leukocytes in adipose 
tissue and the induction of systemic insulin resistance [24].
PATIENTS AND METHODS
About 25 PCOS women (patients) and 25 healthy subjects (control 
group) were enrolled in this study. Blood was collected from Kamal- Al 
SamarraiHospital/Baghdad. In the biochemical test, the blood was 
separated by centrifugation then in test tubes which were marked 
with names of patients and control group then frozen at −20°C. Then, 
MCP, hemoglobin (Hb), packed cell volume (PCV), fasting blood glucose 
(FBG), urea, creatinine, prolactin, testosterone, LH, FSH, T3, T4, and 
thyroid-stimulating hormone (TSH) were determined by enzyme-
linked immune-sorbent assay and relevant clinical features were 
collected simultaneously in all subjects.
Statistical analysis
The results were expressed as Mean±standard deviation with p<0.05 
indicated that there was a significant difference when comparing 
between PCOS women and healthy subjects using SPSS-18 program 
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Microsoft. Correlation coefficients test was done between groups; the 
significant correlation between values was expressed as p<0.05.
RESULTS AND DISCUSSION
Patients with PCOS suffered irregularity in a menstrual cycle which 
usually either amenorrhea or oligomenorrhea, patients with PCOS 
suffered from symptoms such as depression, acne, and hirsutism in 
varying intensity as shown in Table 1.
In this study, the results showed no significant increase in the means 
of age and body mass index in patients when compared with healthy 
subjects as shown in Table 2.
There was no significant decrease in the serum levels of Hb and PCV 
while no significant increase in FBG, urea, and creatinine in PCOS 
patients when compared with the control group as shown in Table 3.
In addition, mean of LH and 17 β-Estradiol were no significantly 
increased except the significant increase in the ratio of LH/FSH, 
prolactin, and testosterone, while FSH was significantly decreased 
in PCOS women when compared with healthy subjects as shown in 
Table 4.
Levels of triiodothyronine (T3), thyroxine (T4) were found to be 
significantly decreased, however, a significant increase in the level 
of TSH was found in patients when compared with healthy subjects. 
Finally, a significant increase was detected in the level of MCP-1 in 
patients when compared with healthy control as shown in Table 5 and 
Fig. 1.
There was a significant correlation between MCP-1 and other clinical 
markers demonstrated in Table 6 and Fig. 2-5.
The increased risk of Type 2 diabetes mellitus (DM) among women 
with PCOS was clarified in a study which was demonstrated to be higher 
compared with healthy subjects, impaired glucose tolerance, insulin 
resistance of tissues (adipose tissue, liver, and skeletal muscle), and 
metabolic syndrome in PCOS women, all these together with irregularities 
in the menstrual cycle (amenorrhea or oligomenorrhea) [25,26]. 
PCOS can be considered a genetic disorder just like T2 DM [27], and it 
has been occurred in one of each five women within the reproductive 
age [28,29]. On the other hand, it was found that high Estradiol levels 
may affect the thyroid cells [30]. In hyperandrogenemia, Testosterone 
level measurement is very important [31]. Besides, it was predicted 
that perpubertal obese girls with hyperandrogenemia had abnormal 
fasting insulin [32], in addition obese patients have higher estrogens 
levels which lead to hirsutism and FSH inhibition because excess 
adipose tissue in those patients can convert androstenedione to estrone 
and testosterone to estradiol through its aromatase enzyme [33]. Mec 
Cartney demonstrated that women with PCOS having higher LH pulse 
abundance and frequency in addition to abnormal LH secretions. Other 
studies found that high insulin levels in 75% of PCOS women may lead 
to hypothalamic pituitary-ovarian axis abnormalities which may result 
in an elevation in LH levels in those patients. On the other hand, it was 
demonstrated that FSH levels in those patients were significantly lower 
than in healthy subjects, these findings agree with some other studies, 
where it is thought that adipose tissue in PCOS patients by increasing 
androstenedione levels, it will lead to LH stimulation and FSH inhibition 
at the same time [34]. In women at the reproductive age who had thyroid 








PCOS: Polycystic ovarian syndrome




Age 24.9±5.646 29.4±5.680 0.6
BMI (Kg/m2) 23.884±2.306 25.101±4.546 0.8
Significant using SPSS for two independent means of significance *(p≤0.05), 
**(p≤0.01). PCOS: Polycystic ovarian syndrome, SD: Standard deviation,  
BMI: Body mass index




PCV (%) 39.933±1.830 38.8±3.707 0.45
Hb 13.493±0.705 12.933±0.983 0.16
FBG mmol/l 4.763±0.370 5.066±0.601 0.82
Urea mmol/l 21.266±1.624 23.41±4.017 0.08
Creatinine mg/dl 0.980 0.1321 1.008±0.164 0.64
Significant using SPSS for two independent means of significance * (p≤0.05), 
** (p≤0.01). PCOS: Polycystic ovarian syndrome, SD: Standard deviation,  
PCV: Packed cell volume, Hb: Hemoglobin, FBG: Fasting blood glucose
Table 4: Testosterone, FSH, LH, prolactin, and estradiol levels in 
PCOS and Control groups
Parameters Mean±SD p
Controls Patients
LH mlU/ml 5.233±5.744 6.966±2.315 0.3
FSH mlU/ml 7.74±4.347 4.212±2.478 0.009**
LH/FSH 0.720±0.649 1.925±1.217 0.005**
Prolactin ng/ml 14.084±11.836 20.821±5.270 0.01**
17 β-estradiol pg/ml 31.733±14.598 38.28±6.924 0.13
Testosterone ng/ml 0.21±0.107 3.990±5.853 0.026*
Significant using SPSS for two independent means of significance *(p≤0.05), 
**(p≤0.01). LH: Luteinizing hormone, FSH: Follicle stimulating hormone
Table 5: T3, T4, TSH, MCP levels in PCOS and control groups
Parameters Mean±SD p
Controls Patients
T3 nmol/ml 1.243±0.248 1.013±0.199 0.02*
T4 nmol/ml 94.190±9.755 81.786±15.19 0.01**
TSH mulu/ml 1.268±0.655 2.128±1.106 0.02*
MCP-1 ng/l 1.975±0.716 3.115±0.681 0.007**
Significant using SPSS for two independent means of significance *(p≤0.05), 
**(p≤0.01). MCP: Monocyte chemoattractant protein, TSH: Thyroid-stimulating 
hormone, PCOS: Polycystic ovarian syndrome
Table 6: Correlation coefficient between clinical markers in 
patients with PCOS
Variable Correlation Sig.(2-tail)
Testosterone and MCP 0.752 0.002**
17 β-Estradiol and T4 −0.654 0.03*
17 β-Estradiol and Prolactin −0.606 0028*
Creatinine and urea 0.758 0.001**
Significant using SPSS for two independent means of significance *(p≤0.05), 
**(p≤0.01)
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disorders, LH/FSH ratio was higher due to the presence of thyroid 
antibody, which may interact with the ovaries through both direct effects 
on ovarian function and autoimmune pathways besides chromo some X 
abnormalities [35]. A profound relationship was found between thyroid 
dysfunction (thyroid volume) and PCOS [36]. The mechanism for this 
relationship is still unclear; however, it might be due to the changes occur 
in LH levels that increased about 50% of PCOS women while FSH levels 
were either normal or decreased [37]. A recent study demonstrated 
that metabolic changes responsible for the significant increment in 
total thyroxine (TT4), total triiodothyronine (TT3), and TSH, besides, 
it was found that total testosterone and TSH levels were significantly 
increased in those patients compared with healthy controls [38,39]. 
This high level of TSH may lead to disorder of FSH receptor [40]. Those 
PCOS women with higher TSH show metabolic syndrome complications 
[41]. On the other hand, recent findings found that ovarian cysts may 
be produced by hypothyroidism and that polycystic behavior of the 
ovaries was relieved by treatment with thyroxine, so, as a conclusion, 
primary hypothyroidism can lead to PCOS-like ovaries [42]. One of 
the mechanisms that lead to the infiltration of leukocytes into sites of 
inflammatory responses is the production of chemotactic molecules that 
diffuse out from the site of release and form concentration gradient to 
which leukocytes respond and migrate, serum from women with PCOS, 
when compared to serum from controls, induced significantly increased 
expression of MCP-1 in THP-1 human monocyte cell line. Several reviews 
concerning the role of MCP-1 in the pathogenesis of many inflammatory 
diseases are already available elsewhere. Macrophages play important 
roles in defense by presenting Ag to lymphocytes or by participating 
in efferent limb immune responses as effecter or secreting cytokines. 
Macrophages infiltrating sites of inflammation are derived from blood 
monocytes, which are attracted by chemotactic factors produced at 
inflammatory sites [43].
CONCLUSION
From the current study, it can be concluded that PCOS women might 
suffer from low-grade chronic inflammation as a result of changes in 
the levels of MCP-1(an inflammation marker). Besides, it was detected 
that TSH might be responsible for all of the irregularities in the levels 
of sex hormones in such patients. Furthermore, PCOS-related metabolic 
disturbances could be related to TSH and MCP which can be considered 
as relevant features in such disturbances.
Recommendations
In subjects who have high risk of developing PCOS at a very young 
age, it is important to keep in mind all the abnormalities that could be 
occurred in metabolic (such as adiposity and hyperinsulinemia) and 
endocrine (includes adrenal and ovarian) functions during this disease 
and to find reliable markers that can give a clear diagnosis of such 
disorders in early childhood prior the development of PCOS.
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